Eliquis (Apixaban) Clinical Trials
The approved indications for ELIQUIS are based on a robust
clinical trial programme1–7
Eliquis is indicated for:
-
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II)1
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1
Please click here to access the ELIQUIS Patient Information Leaflet.
ADVANCE-2 = Apixaban Dosed Orally Versus Anticoagulation with Enoxaparin 2
ADVANCE-3 = Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism 3
ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation
AVERROES = Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment
AMPLIFY = Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy
AMPLIFY-EXT = Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment
References
- ELIQUIS® (apixaban) Summary of Product Characteristics.
- Lassen MR et al. Lancet 2010; 375: 807–815.
- Lassen MR et al. N Engl J Med 2010; 363: 2487–2498.
- Granger CB et al. N Engl J Med 2011; 365: 981–992.
- Connolly SJ et al. N Engl J Med 2011; 364: 806–817.
- Agnelli G et al. N Engl J Med 2013; 369: 799–808.
- Agnelli G et al. N Engl J Med 2013; 368: 699–708.